Analysis: Becton, Dickinson and Company

US:BDX

Why is Becton, Dickinson and Company stock rising?

  • Fiscal 2026 guidance raise toward high-end low single-digit revenue and higher adjusted EPS midpoint
  • New EMS collaboration and semaglutide launch using Vystra injection pen in Brazil
  • Expanded U.S./Europe launch of HemoSphere Stream Module extending noninvasive monitoring beyond traditional care settings
  • Revello Vascular Covered Stent European launch with U.S. launch planned next fiscal year

Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Becton, Dickinson and Company and 4,900+ companies.

Sign in
5-day free pass. No card required.